Life Disrupted: Role of Advanced Practice Providers in Guiding Patients with Crohn’s Disease Through the Challenges of Bowel Urgency

Statement of Need

Up to 80% of patients with Crohn’s disease (CD) report some degree of bowel urgency, a symptom that not only significantly adds to their overall emotional and social burden but can be an indicator of uncontrolled bowel inflammation. Unfortunately, bowel urgency is largely underrecognized by health care professionals (HCPs) caring for patients with CD. Nurse practitioners (NPs) and physician associates (PAs) in the gastroenterology field are positioned to initiate screening for bowel urgency as part of thorough symptom evaluation while establishing open communication with patients and implementing shared decision-making.

In this CME Outfitters recorded webcast, leading clinical experts will help prepare learners to discuss, assess, and address bowel urgency in patients with CD, and will provide insight into the efficacy and safety of new and emerging therapies. The webcast will also include videos capturing the patient journey and first-hand experiences.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

Identify the contributions of bowel urgency, fatigue, psychosocial symptoms, and histologic/endoscopic healing in the burden of CD and their effects on patient QoL
Evaluate bowel urgency, fatigue, psychosocial symptoms, and histologic/endoscopic healing for patients with CD as part of thorough symptom evaluation
Engage patients in open communication about their bowel urgency, fatigue, psychosocial symptoms, and histologic/endoscopic healing with the goal of improving clinical outcomes

Financial Support

This activity is supported by an educational grant from Lilly.

Target Audience

Primary: Gastroenterology nurse practitioners (NPs) and physician associates (PAs)
Secondary: Nurses and pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 1.0

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.

Nurses (ANCC) 1.0

This activity is designated for 1.00 contact hour.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

Pharmacists (ACPE) 1.0

This application-based activity is approved for 1.00 contact hour (0.1 CEUs) of continuing pharmacy credit (JA0007185-0000-24-028-H01-P).

PAs (AAPA) 1.00

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until 05/09/2025. PAs should only claim credit commensurate with the extent of their participation.

Disclosure Declaration

Ms. Orleck reports the following financial relationships:

Advisory Board: AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Lilly; and Salix Pharmaceuticals

Consultant: Bristol Myers Squibb Company and Pfizer Inc.

Speakers Bureau: AbbVie Inc.; Ardelyx; Janssen Pharmaceuticals, Inc.; Lilly; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.

Dr. Naik reports the following financial relationships:

Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Eli Lilly & Company; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: AbbVie Inc.; Bristol Myers Squibb Company; Eli Lilly & Company; and Takeda Pharmaceuticals U.S.A., Inc.

Dr. Wolgamott reports the following financial relationships:

Consultant: AbbVie Inc.; Ardelyx; Bristol Myers Squibb Company; Evoke Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Madrigal Pharmaceuticals; Nestle Health Science; Novo Nordisk; Pfizer Inc.; and Salix Pharmaceuticals

Speakers Bureau: AbbVie Inc.; Ardelyx; Bristol Myers Squibb; Evoke Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Madrigal Pharmaceuticals; Nestle Health Science; and Salix Pharmaceuticals

Sub-Investigator: Clinical Research Institute of Michigan

Ms. Aswani-Omprakash reports the following financial relationships:

Advisory Board: Ardelyx; Genentech Inc./Roche; Johnson & Johnson; Parexel; Pfizer Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Tillotts Pharma AG

Consultant: AbbVie Inc.; Boehringer Ingelheim; Convatec Inc.; Genentech Inc./Roche; Hollister Incorporated.; Johnson & Johnson; Parexel; and Walgreens Co.

Speakers Bureau: AbbVie Inc.; Boehringer Ingelheim; Iterative Health; Genentech Inc./Roche; Hollister Incorporatedion; Iterative Health; Johnson & Johnson; Parexel; and Takeda Pharmaceuticals U.S.A., Inc.

Employment:
Senior Director of Strategic Partnerships at Sommer Consulting

The following individuals have no financial relationships to disclose:

Jeffrey Helfand, DO (Peer Reviewer)
Amanda K. Smith, PA-C (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Susan Perry (Planning Committee)
Kasey Brandt, PharmD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

WCV-083-050924-11